

# Mark S Freedman

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11861381/mark-s-freedman-publications-by-year.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

|                    |                          |                |                 |
|--------------------|--------------------------|----------------|-----------------|
| 181<br>papers      | 14,680<br>citations      | 52<br>h-index  | 119<br>g-index  |
| 191<br>ext. papers | 18,011<br>ext. citations | 7.3<br>avg, IF | 6.24<br>L-index |

| #   | Paper                                                                                                                                                                                                                                               | IF   | Citations |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 181 | Neurophysiological outcomes following mesenchymal stem cell therapy in multiple sclerosis.. <i>Clinical Neurophysiology</i> , <b>2022</b> , 136, 69-81                                                                                              | 4.3  |           |
| 180 | High or increasing serum NFL is predictive of impending multiple sclerosis relapses.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 59, 103535                                                                                    | 4    | 3         |
| 179 | Body mass index as a predictor of MS activity and progression among participants in BENEFIT.. <i>Multiple Sclerosis Journal</i> , <b>2022</b> , 13524585211061861                                                                                   | 5    | 1         |
| 178 | Mesenchymal stem cell therapy and cognition in MS: Preliminary findings from a phase II clinical trial.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 61, 103779                                                                 | 4    | 0         |
| 177 | Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis, the Ottawa Protocol.. <i>Current Protocols</i> , <b>2022</b> , 2, e437                                                                                                   |      |           |
| 176 | Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 27, 167-173                                                                                     | 5    | 1         |
| 175 | Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. <i>Lancet Neurology</i> , <b>2021</b> , 20, 917-929 <sup>24.1</sup>                |      | 9         |
| 174 | Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis. <i>CNS Drugs</i> , <b>2021</b> , 35, 385-402                                                                                                                                    | 6.7  | 11        |
| 173 | MAGNIMS score predicts long-term clinical disease activity-free status and confirmed disability progression in patients treated with subcutaneous interferon beta-1a. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 49, 102790    | 4    | 1         |
| 172 | Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. <i>JAMA Neurology</i> , <b>2021</b> , 78, 558-567                                  | 17.2 | 39        |
| 171 | Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>2021</b> , 421, 117324                                                        | 3.2  | 0         |
| 170 | Serum neurofilament light in MS: The first true blood-based biomarker?. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 1352458521993066                                                                                                          | 5    | 11        |
| 169 | Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation. <i>Frontiers in Neuroscience</i> , <b>2021</b> , 15, 654942                                                                                                     | 5.1  | 11        |
| 168 | A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 52, 102945                                                                                | 4    | 4         |
| 167 | Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211035740           | 5    | 2         |
| 166 | Pharmacodynamic biomarkers of long-term interferon beta-1a therapy in REFLEX and REFLEXION. <i>Journal of Neuroimmunology</i> , <b>2021</b> , 360, 577715                                                                                           | 3.5  | 0         |
| 165 | Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2021</b> , 7, 2055217321990852 | 2    | 1         |

|     |                                                                                                                                                                                                                                                                                                 |      |    |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----|
| 164 | Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. <i>Canadian Journal of Neurological Sciences</i> , <b>2020</b> , 47, 437-455                                                                                                                           | 1    | 18 |
| 163 | COVID-19 in teriflunomide-treated patients with multiple sclerosis. <i>Journal of Neurology</i> , <b>2020</b> , 267, 2796-2796                                                                                                                                                                  | 3    | 37 |
| 162 | Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. <i>Scientific Reports</i> , <b>2020</b> , 10, 10381                                                                                                                                                 | 4.9  | 35 |
| 161 | Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 540-547                                                                                                                         | 5    | 13 |
| 160 | Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. <i>CNS Drugs</i> , <b>2020</b> , 34, 185-196 | 6.7  | 32 |
| 159 | Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2020</b> , 6, 2055217320972137                    | 2    | 2  |
| 158 | A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study. <i>Journal of Medical Internet Research</i> , <b>2020</b> , 22, e16932                                                                                | 7.6  | 20 |
| 157 | Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1729-1739                                                                       | 5    | 22 |
| 156 | Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis. <i>BMC Neurology</i> , <b>2020</b> , 20, 364                                                                                                                                                  | 3.1  | 1  |
| 155 | Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , <b>2020</b> , 19, 988-997                                                                     | 24.1 | 28 |
| 154 | Blood Neurofilament Light Chain: The Neurologist's Troponin?. <i>Biomedicines</i> , <b>2020</b> , 8,                                                                                                                                                                                            | 4.8  | 18 |
| 153 | Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study. <i>Multiple Sclerosis and Related Disorders</i> , <b>2020</b> , 46, 102438                                                                                | 4    | 7  |
| 152 | Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1083-1092                                                                                                | 5    | 15 |
| 151 | Does Resetting the Immune System Fix Multiple Sclerosis?. <i>Canadian Journal of Neurological Sciences</i> , <b>2020</b> , 47, 1-10                                                                                                                                                             | 1    | 4  |
| 150 | Clinical and MRI efficacy of sc IFN $\beta$ 1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS. <i>Journal of Neurology</i> , <b>2020</b> , 267, 64-75                                                         | 5.5  | 1  |
| 149 | Imaging cognitive fatigability in multiple sclerosis: objective quantification of cerebral blood flow during a task of sustained attention using ASL perfusion fMRI. <i>Brain Imaging and Behavior</i> , <b>2020</b> , 14, 2417-2428                                                            | 4.1  | 9  |
| 148 | Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 767-775                                                                                                                                  | 5.3  | 10 |
| 147 | Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT. <i>Neurology</i> , <b>2020</b> , 94, e1950-e1960                                                                                                                                              | 6.5  | 10 |

|     |                                                                                                                                                                                                                                                                        |      |      |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|------|
| 146 | Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 33, 131-138                                                                 | 4    | 12   |
| 145 | MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. <i>Trials</i> , <b>2019</b> , 20, 263                           | 2.8  | 41   |
| 144 | Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 845-854 | 4.7  | 46   |
| 143 | Research-to-Practice Gaps in Multiple Sclerosis Care for Patients with Subjective Cognitive, Mental Health, and Psychosocial Concerns in a Canadian Center. <i>International Journal of MS Care</i> , <b>2019</b> , 21, 243-248                                        | 2.3  | 3    |
| 142 | No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon $\beta$ 1a. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 39, 101891                                                                       | 4    | 1    |
| 141 | High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2019</b> , 6, e598                                                                                  | 9.1  | 26   |
| 140 | Machine learning in secondary progressive multiple sclerosis: an improved predictive model for short-term disability progression. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2019</b> , 5, 2055217319885983                     | 2    | 12   |
| 139 | MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry. <i>Brain Imaging and Behavior</i> , <b>2019</b> , 13, 1361-1374                                                          | 4.1  | 14   |
| 138 | Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study. <i>Journal of Clinical Neuroscience</i> , <b>2019</b> , 59, 229-231                                                 | 2.2  | 1    |
| 137 | Autologous hematopoietic stem cell transplantation improves fatigue in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 1764-1772                                                                                                             | 5    | 9    |
| 136 | Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Sclerosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2019</b> , 9,                                                                                                       | 5.4  | 13   |
| 135 | Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. <i>Multiple Sclerosis Journal</i> , <b>2019</b> , 25, 565-573                                                       | 5    | 4    |
| 134 | Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , <b>2018</b> , 17, 162-173                                                                                                                                          | 24.1 | 2419 |
| 133 | Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study. <i>Annals of Clinical and Translational Neurology</i> , <b>2018</b> , 5, 346-356                                                                    | 5.3  | 13   |
| 132 | Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology</i> , <b>2018</b> , 17, 405-415                     | 24.1 | 150  |
| 131 | The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 535-539                                       | 5    | 11   |
| 130 | Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 1055-1066                                                                | 5    | 6    |
| 129 | Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 834                                                                    | 8.4  | 28   |

|     |                                                                                                                                                                                                                                                                           |      |     |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----|
| 128 | Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing. <i>Canadian Journal of Neurological Sciences</i> , <b>2018</b> , 45, 489-503                                                                                                             | 1    | 25  |
| 127 | Tolerability and discontinuation rates in teriflunomide-treated patients. A real-world clinical experience. <i>Journal of King Abdulaziz University, Islamic Economics</i> , <b>2018</b> , 23, 204-207                                                                    | 1.1  | 2   |
| 126 | Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2018</b> , 4, 2055217318775236                                                                      | 2    | 1   |
| 125 | The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis. <i>Journal of Neuro-Ophthalmology</i> , <b>2018</b> , 38, 210-216                                                                                                                 | 2.6  | 4   |
| 124 | Disability progression in aggressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 456-463                                                                                                                                                    | 5    | 11  |
| 123 | Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 420-431                                                                                                                        | 5    | 22  |
| 122 | The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2017</b> , 23, 94-105                                                                                                  | 5    | 56  |
| 121 | Subcutaneous interferon $\beta$ 1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, 285-294 | 5.5  | 23  |
| 120 | Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. <i>JAMA Neurology</i> , <b>2017</b> , 74, 459-469                                                                                                                     | 17.2 | 147 |
| 119 | Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study. <i>Journal of Neurology</i> , <b>2017</b> , 264, 1068-1075                                                                                                                      | 5.5  | 18  |
| 118 | Sodium intake and multiple sclerosis activity and progression in BENEFIT. <i>Annals of Neurology</i> , <b>2017</b> , 82, 20-29                                                                                                                                            | 9.4  | 50  |
| 117 | Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 2122-2133                                                                                                                       | 59.2 | 111 |
| 116 | Immunoablation and aHSCT for aggressive multiple sclerosis - AuthorsReply. <i>Lancet, The</i> , <b>2017</b> , 389, 908                                                                                                                                                    | 40   | 1   |
| 115 | A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2017</b> , 3, 2055217317730096                                                     | 2    | 15  |
| 114 | The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2017</b> , 3, 2055217317732802 | 2    | 17  |
| 113 | Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis. <i>Neurotherapeutics</i> , <b>2017</b> , 14, 888-893                                                                                     | 6.4  | 12  |
| 112 | Early MRI results and odds of attaining no evidence of disease activity status in MS patients treated with interferon $\beta$ 1a in the EVIDENCE study. <i>Journal of the Neurological Sciences</i> , <b>2017</b> , 379, 151-156                                          | 3.2  | 8   |
| 111 | Multiple sclerosis: Is there a safe time to discontinue therapy in MS?. <i>Nature Reviews Neurology</i> , <b>2016</b> , 13, 10-11                                                                                                                                         | 15   | 2   |

|     |                                                                                                                                                                                                                                                                                                      |      |     |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----|
| 110 | The evaluation of MRI diffusion values of active demyelinating lesions in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 10, 97-102                                                                                                                             | 4    | 10  |
| 109 | Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. <i>Lancet, The</i> , <b>2016</b> , 388, 576-85                                                                                                     | 4.0  | 234 |
| 108 | Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studies. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 7, 33-40                                                          | 4    | 17  |
| 107 | Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. <i>Therapeutic Advances in Chronic Disease</i> , <b>2016</b> , 7, 18-33                                                                                             | 4.9  | 57  |
| 106 | Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2016</b> , 387, 1075-1084                                                                                                                | 4.0  | 271 |
| 105 | Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): Canadian contribution to the international validation project. <i>Journal of the Neurological Sciences</i> , <b>2016</b> , 362, 147-52                                                                                     | 3.2  | 44  |
| 104 | Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. <i>Neurology</i> , <b>2016</b> , 86, 920-30                                                                                                                                                       | 6.5  | 80  |
| 103 | Inclusion of brain volume loss in a revised measure of No evidence of disease activityS(NEDA-4) in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2016</b> , 22, 1297-305                                                                                            | 5    | 169 |
| 102 | Severe, Highly Active, or Aggressive Multiple Sclerosis. <i>CONTINUUM Lifelong Learning in Neurology</i> , <b>2016</b> , 22, 761-84                                                                                                                                                                  | 3    | 11  |
| 101 | Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. <i>JAMA Neurology</i> , <b>2016</b> , 73, 1089-98                                                                                   | 17.2 | 67  |
| 100 | Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 10, 204-212 | 4    | 28  |
| 99  | Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 5, 97-104                                                                                                                     | 4    | 59  |
| 98  | The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. <i>Neurology</i> , <b>2016</b> , 87, 978-875                                                                                                                                                                            | 7.5  | 78  |
| 97  | Evaluating response to disease-modifying therapy in relapsing multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , <b>2015</b> , 15, 407-23                                                                                                                                               | 4.3  | 4   |
| 96  | Neuro-oncology dilemma: Tumour or tumefactive demyelinating lesion. <i>Multiple Sclerosis and Related Disorders</i> , <b>2015</b> , 4, 555-66                                                                                                                                                        | 4    | 24  |
| 95  | No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. <i>Neurology</i> , <b>2015</b> , 85, 1694-701                                                                                                                                                      | 6.5  | 39  |
| 94  | Aggressive multiple sclerosis: proposed definition and treatment algorithm. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 379-89                                                                                                                                                               | 15   | 82  |
| 93  | Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology, The</i> , <b>2014</b> , 13, 247-56                                                                                                    | 24.1 | 363 |



|    |                                                                                                                                                                                                                                                   |      |      |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|------|
| 92 | Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization. <i>Journal of the Neurological Sciences</i> , <b>2014</b> , 339, 196-206                                             | 3.2  | 21   |
| 91 | Vitamin D as an early predictor of multiple sclerosis activity and progression. <i>JAMA Neurology</i> , <b>2014</b> , 71, 306-14                                                                                                                  | 17.2 | 312  |
| 90 | Molecular mechanism underlying the impact of vitamin D on disease activity of MS. <i>Annals of Clinical and Translational Neurology</i> , <b>2014</b> , 1, 605-17                                                                                 | 5.3  | 39   |
| 89 | Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. <i>Multiple Sclerosis and Related Disorders</i> , <b>2014</b> , 3, 696-704                     | 4    | 76   |
| 88 | Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. <i>Journal of Neurology</i> , <b>2014</b> , 261, 1781-8                                                                      | 5.5  | 20   |
| 87 | Teriflunomide: a novel oral treatment for relapsing multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 1019-27                                                                                                      | 4    | 13   |
| 86 | Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , <b>2014</b> , 13, 977-86                         | 24.1 | 208  |
| 85 | Defining the clinical course of multiple sclerosis: the 2013 revisions. <i>Neurology</i> , <b>2014</b> , 83, 278-86                                                                                                                               | 6.5  | 1632 |
| 84 | Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. <i>Lancet Neurology</i> , <b>2014</b> , 13, 257-67                | 24.1 | 156  |
| 83 | Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2014</b> , 7, 279-88 | 6.6  | 9    |
| 82 | Efficacy and safety of subcutaneous interferon-β1a in patients with a first demyelinating event and early multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , <b>2014</b> , 14, 1207-14                                             | 5.4  | 4    |
| 81 | Efficacy of subcutaneous interferon β1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, 647-53                      | 5.5  | 16   |
| 80 | Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2014</b> , 85, 1198-208                                                                      | 5.5  | 105  |
| 79 | Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 234-42                                                                                        | 5    | 17   |
| 78 | Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 705-16                                          | 5    | 237  |
| 77 | Cognitive fatigue in individuals with multiple sclerosis undergoing immunoablative therapy and hematopoietic stem cell transplantation. <i>Journal of the Neurological Sciences</i> , <b>2014</b> , 336, 132-7                                    | 3.2  | 9    |
| 76 | Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , <b>2014</b> , 3, 147-55                                | 4    | 43   |
| 75 | Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. <i>Lancet Neurology</i> , <b>2014</b> , 13, 353-63                                                                                        | 24.1 | 212  |

|    |                                                                                                                                                                                                                                                                   |      |     |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----|
| 74 | Patient subgroup analyses of the treatment effect of subcutaneous interferon $\beta$ 1a on development of multiple sclerosis in the randomized controlled REFLEX study. <i>Journal of Neurology</i> , <b>2014</b> , 261, 490-9                                    | 5.5  | 12  |
| 73 | Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. <i>Journal of Neurology</i> , <b>2013</b> , 260, 2472-80                                                                                                           | 5.5  | 31  |
| 72 | Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned. <i>Neurotherapeutics</i> , <b>2013</b> , 10, 68-76                                                                                                                                | 6.4  | 59  |
| 71 | Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. <i>Annals of Neurology</i> , <b>2013</b> , 73, 341-54                                                                           | 9.4  | 105 |
| 70 | Mesenchymal stem cells as treatment for MS - progress to date. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 515-9                                                                                                                                        | 5    | 50  |
| 69 | Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. <i>Lancet Neurology</i> , <b>2013</b> , 12, 756-67                                                                               | 24.1 | 163 |
| 68 | Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1310-9                                                                                                                         | 5    | 60  |
| 67 | Characterising aggressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2013</b> , 84, 1192-8                                                                                                                                 | 5.5  | 51  |
| 66 | Present and emerging therapies for multiple sclerosis. <i>CONTINUUM Lifelong Learning in Neurology</i> , <b>2013</b> , 19, 968-91                                                                                                                                 | 3    | 6   |
| 65 | Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. <i>Neurology</i> , <b>2013</b> , 81, 552-8                                                                                                                      | 6.5  | 90  |
| 64 | Cognition in early relapsing-remitting multiple sclerosis: consequences may be relative to working memory. <i>Journal of the International Neuropsychological Society</i> , <b>2013</b> , 19, 938-49                                                              | 3.1  | 14  |
| 63 | Teriflunomide in relapsing multiple sclerosis: therapeutic utility. <i>Therapeutic Advances in Chronic Disease</i> , <b>2013</b> , 4, 192-205                                                                                                                     | 4.9  | 22  |
| 62 | Treatment optimization in MS: Canadian MS Working Group updated recommendations. <i>Canadian Journal of Neurological Sciences</i> , <b>2013</b> , 40, 307-23                                                                                                      | 1    | 159 |
| 61 | Utility of the Canadian Treatment Optimization Recommendations (TOR) in MS care. <i>Canadian Journal of Neurological Sciences</i> , <b>2013</b> , 40, 527-35                                                                                                      | 1    | 6   |
| 60 | Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. <i>Journal of Clinical &amp; Cellular Immunology</i> , <b>2013</b> , 4,                                                                                            | 2.7  | 28  |
| 59 | Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. <i>Journal of Clinical &amp; Cellular Immunology</i> , <b>2013</b> , 04,                                                                                           | 2.7  | 55  |
| 58 | Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. <i>Lancet Neurology</i> , <b>2012</b> , 11, 33-41 | 24.1 | 153 |
| 57 | Neurorepair with mesenchymal stem cells: hope or hype?. <i>Lancet Neurology</i> , <b>2012</b> , 11, 123-5                                                                                                                                                         | 24.1 | 11  |



|    |                                                                                                                                                                                                                                                |      |     |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----|
| 56 | Disease-specific therapy of idiopathic inflammatory demyelinating disorders. <i>Expert Review of Neurotherapeutics</i> , <b>2012</b> , 12, 1113-24                                                                                             | 4.3  | 2   |
| 55 | Cerebrospinal fluid myelin basic protein is frequently ordered but has little value: a test utilization study. <i>American Journal of Clinical Pathology</i> , <b>2012</b> , 138, 262-72                                                       | 1.9  | 18  |
| 54 | Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 1278-89                                       | 5    | 112 |
| 53 | Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMPO) of oral teriflunomide in relapsing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 1625-32                                           | 5    | 66  |
| 52 | Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 1466-71                                                          | 5    | 47  |
| 51 | Tests of information processing speed: what do people with multiple sclerosis think about them?. <i>International Journal of MS Care</i> , <b>2012</b> , 14, 92-9                                                                              | 2.3  | 16  |
| 50 | Managing relapsing-remitting multiple sclerosis following first drug failure. <i>Neurodegenerative Disease Management</i> , <b>2011</b> , 1, 115-126                                                                                           | 2.8  |     |
| 49 | Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. <i>Lancet Neurology</i> , <b>2011</b> , 10, 649-56                                                                                             | 24.1 | 231 |
| 48 | T cells and multiple sclerosis: Friends, foes, or both?. <i>Autoimmunity Reviews</i> , <b>2011</b> , 10, 364-7                                                                                                                                 | 13.6 | 7   |
| 47 | Multiple sclerosis therapeutic strategies: Use second-line agents as first-line agents when time is of the essence. <i>Neurology: Clinical Practice</i> , <b>2011</b> , 1, 66-68                                                               | 1.7  | 10  |
| 46 | Randomized trial of oral teriflunomide for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1293-303                                                                                                  | 59.2 | 662 |
| 45 | Improving long-term follow-up studies of immunomodulatory therapies. <i>Neurology</i> , <b>2011</b> , 76, S35-8                                                                                                                                | 6.5  | 6   |
| 44 | The Computerized Test of Information Processing (CTIP) offers an alternative to the PASAT for assessing cognitive processing speed in individuals with multiple sclerosis. <i>Cognitive and Behavioral Neurology</i> , <b>2010</b> , 23, 192-8 | 1.6  | 24  |
| 43 | Using retinal architecture to help characterize multiple sclerosis patients. <i>Canadian Journal of Ophthalmology</i> , <b>2010</b> , 45, 520-6                                                                                                | 1.4  | 43  |
| 42 | The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 503-10                 | 5    | 185 |
| 41 | Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> , 16, 1076-83              | 4.7  | 32  |
| 40 | Therapy of MS. <i>Clinical Neurology and Neurosurgery</i> , <b>2010</b> , 112, 365-85                                                                                                                                                          | 2    | 74  |
| 39 | Chronic cerebrospinal venous insufficiency and multiple sclerosis. <i>Annals of Neurology</i> , <b>2010</b> , 67, 286-90                                                                                                                       | 9.4  | 107 |

|    |                                                                                                                                                                                                                                              |      |     |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----|
| 38 | Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. <i>Annals of Neurology</i> , <b>2010</b> , 68, 540-5                                                                                       | 9.4  | 60  |
| 37 | Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. <i>Archives of Neurology</i> , <b>2009</b> , 66, 1345-52                                                                                     |      | 28  |
| 36 | MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. <i>BMC Neurology</i> , <b>2009</b> , 9, 19                                                                     | 3.1  | 15  |
| 35 | Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. <i>Lancet Neurology</i> , <b>2009</b> , 8, 987-97 | 24.1 | 279 |
| 34 | Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. <i>Annals of Neurology</i> , <b>2009</b> , 66, 460-71                                          | 9.4  | 629 |
| 33 | The prognostic significance of cerebrospinal fluid in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , <b>2009</b> , 279, 21-5                                                                                              | 3.2  | 55  |
| 32 | Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 2459-70                                                                 | 2.5  | 21  |
| 31 | CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis. <i>Clinical Immunology</i> , <b>2008</b> , 128, 219-27                                             | 9    | 35  |
| 30 | Correlation of specialized CD16(+) gammadelta T cells with disease course and severity in multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2008</b> , 194, 147-52                                                                  | 3.5  | 25  |
| 29 | Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. <i>European Neurology</i> , <b>2008</b> , 60, 1-11                                                                               | 2.1  | 41  |
| 28 | Induction vs. escalation of therapy for relapsing multiple sclerosis: the evidence. <i>Neurological Sciences</i> , <b>2008</b> , 29 Suppl 2, S250-2                                                                                          | 3.5  | 16  |
| 27 | Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. <i>Journal of Neurology</i> , <b>2008</b> , 255, 480-7                                                                                     | 5.5  | 58  |
| 26 | Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. <i>Annals of Neurology</i> , <b>2008</b> , 63, 254-62                                                                             | 9.4  | 142 |
| 25 | Bone marrow transplantation: does it stop MS progression?. <i>Journal of the Neurological Sciences</i> , <b>2007</b> , 259, 85-9                                                                                                             | 3.2  | 16  |
| 24 | Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. <i>Archives of Neurology</i> , <b>2007</b> , 64, 1292-8                                                                            |      | 41  |
| 23 | Reaction time: An alternative method for assessing the effects of multiple sclerosis on information processing speed. <i>Archives of Clinical Neuropsychology</i> , <b>2007</b> , 22, 655-64                                                 | 2.7  | 59  |
| 22 | Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. <i>Lancet</i> , <b>2007</b> , 370, 389-97         | 4.0  | 417 |
| 21 | Quantifying axonal loss after optic neuritis with optical coherence tomography. <i>Annals of Neurology</i> , <b>2006</b> , 59, 963-9                                                                                                         | 9.4  | 466 |

|    |                                                                                                                                                                                                                                            |     |     |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|
| 20 | Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. <i>Multiple Sclerosis Journal</i> , <b>2005</b> , 11, 227-31                                    | 5   | 24  |
| 19 | Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. <i>Archives of Neurology</i> , <b>2005</b> , 62, 865-70                                                                |     | 348 |
| 18 | Treatment optimization in multiple sclerosis. <i>Canadian Journal of Neurological Sciences</i> , <b>2004</b> , 31, 157-68                                                                                                                  |     | 93  |
| 17 | Study of Herpesvirus saimiri immortalization of gammadelta T cells derived from peripheral blood and CSF of multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , <b>2003</b> , 139, 119-32                                     | 3.5 | 3   |
| 16 | gamma/delta T cells in multiple sclerosis: chemokine and chemokine receptor expression. <i>Clinical Immunology</i> , <b>2002</b> , 103, 309-16                                                                                             | 9   | 18  |
| 15 | Mechanism of gammadelta T cell-induced human oligodendrocyte cytotoxicity: relevance to multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>1998</b> , 87, 49-61                                                                    | 3.5 | 48  |
| 14 | gamma delta T-cell-human glial cell interactions. I. In vitro induction of gammadelta T-cell expansion by human glial cells. <i>Journal of Neuroimmunology</i> , <b>1997</b> , 74, 135-42                                                  | 3.5 | 24  |
| 13 | gamma delta T-cell-human glial cell interactions. II. Relationship between heat shock protein expression and susceptibility to cytolysis. <i>Journal of Neuroimmunology</i> , <b>1997</b> , 74, 143-8                                      | 3.5 | 17  |
| 12 | Cytokine induction of heat shock protein expression in human oligodendrocytes: an interleukin-1-mediated mechanism. <i>Journal of Neuroimmunology</i> , <b>1994</b> , 50, 17-24                                                            | 3.5 | 69  |
| 11 | Production of soluble autocrine inhibitory factors by human glioma cell lines. <i>Journal of the Neurological Sciences</i> , <b>1992</b> , 110, 178-85                                                                                     | 3.2 | 26  |
| 10 | Differential expression of heat shock proteins by human glial cells. <i>Journal of Neuroimmunology</i> , <b>1992</b> , 41, 231-8                                                                                                           | 3.5 | 59  |
| 9  | Differential responses of CD4+CD45RA+ and CD4+CD29+ subsets to activated CD8+ cells: enhanced stimulation of the CD4+CD45RA+ subset by cells from patients with multiple sclerosis. <i>Cellular Immunology</i> , <b>1991</b> , 133, 306-16 | 4.4 | 9   |
| 8  | Peripheral blood gamma-delta T cells lyse fresh human brain-derived oligodendrocytes. <i>Annals of Neurology</i> , <b>1991</b> , 30, 794-800                                                                                               | 9.4 | 112 |
| 7  | Phenotypic and functional characteristics of activated CD8+ cells: a CD11b-CD28- subset mediates noncytolytic functional suppression. <i>Clinical Immunology and Immunopathology</i> , <b>1991</b> , 60, 254-67                            |     | 20  |
| 6  | The role of heat shock proteins in oligodendrocyte/T cell interaction. <i>Journal of Neuroimmunology</i> , <b>1991</b> , 35, 112                                                                                                           | 3.5 | 2   |
| 5  | Immunoregulatory properties of T-cell lines derived from the systemic and intrathecal compartments: a phenotypic and functional study. <i>Annals of Neurology</i> , <b>1990</b> , 27, 258-65                                               | 9.4 | 16  |
| 4  | Human oligodendrocytes are susceptible to cytolysis by major histocompatibility complex class I-restricted lymphocytes. <i>Journal of Neuroimmunology</i> , <b>1990</b> , 27, 89-97                                                        | 3.5 | 41  |
| 3  | Vascular headache: a presenting symptom of multiple sclerosis. <i>Canadian Journal of Neurological Sciences</i> , <b>1989</b> , 16, 63-6                                                                                                   | 1   | 48  |

|   |                                                                                                                                                                 |     |    |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----|
| 2 | Herpes zoster ophthalmicus with delayed cerebral infarction and meningoencephalitis. <i>Canadian Journal of Neurological Sciences</i> , <b>1987</b> , 14, 312-4 | 1   | 11 |
| 1 | Selective effects of LSD and hyperthermia on the synthesis of synaptic proteins and glycoproteins. <i>Brain Research</i> , <b>1981</b> , 207, 129-45            | 3-7 | 44 |